May 3 (Reuters) - Roivant Sciences said on Monday it would go public through a merger with blank-check firm Montes Archimedes Acquisition Corp in a deal that values the biotech company at $7.3 billion. (Reporting by Niket Nishant in Bengaluru; Editing by Ramakrishnan M.) Our Standards: The Thomson Reuters Trust Principles.